An Open-Label Study to Explore the Safety, Efficacy and Pharmacokinetics of TMC207 in Japanese Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
Phase of Trial: Phase II
Latest Information Update: 16 May 2017
At a glance
- Drugs Bedaquiline (Primary) ; Antituberculars
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 22 Dec 2016 Planned End Date changed from 1 Nov 2018 to 1 Sep 2020.
- 22 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Jul 2018.
- 22 Mar 2016 Planned End Date changed from 1 Aug 2018 to 1 Nov 2018, according to ClinicalTrials.gov record.